Difference in efficacy of osimertinib between patients with EGFR-positive NSCLC with postoperative recurrence and those with de novo unresectable disease: A prospective, observational study
- 26 November 2024
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 198, 108037
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca KK
This publication has 25 references indexed in Scilit:
- The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study)JTO Clinical and Research Reports, 2024
- Overall Survival Among Patients With De Novo Stage IV Metastatic and Distant Metastatic Recurrent Non–Small Cell Lung CancerJAMA Network Open, 2023
- MetastasisCell, 2023
- Lung cancerThe Lancet, 2021
- Tumour heterogeneity and metastasis at single-cell resolutionNature Cell Biology, 2018
- Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness studyLung Cancer, 2018
- Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 studyThe Lancet Oncology, 2018
- Treatment Patterns and Health Resource Utilization Among Patients Diagnosed With Early Stage Resected Non–Small Cell Lung Cancer at US Community Oncology PracticesClinical Lung Cancer, 2015
- The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptorInternational Journal of Clinical Oncology, 2014
- Local recurrence after surgery for early stage lung cancerCancer, 2009